Synthetic lethal mutations in the cyclin A interface of human cytomegalovirus

Henry Weisbach1, Christoph Schablowsky1, Barbara Vetter1

  • 1Charité Universitätsmedizin Berlin, Labor für Pädiatrische Molekularbiologie, Berlin, Germany.

Plos Pathogens
|January 28, 2017
PubMed

Insights

Human cytomegalovirus (HCMV) uses pp150 to control cell cycle progression, preventing viral replication in S/G2 phases. This strategy, involving pp150 and pUL21a, is crucial for efficient HCMV infection.

Area of Science:

  • Virology
  • Cell Biology
  • Molecular Biology

Background:

  • Host-pathogen interactions involve a balance between host restriction factors and viral countermeasures.
  • Human cytomegalovirus (HCMV) exhibits complex regulation of its replication cycle.
  • Viral proteins can manipulate host cell processes to facilitate infection.

Purpose of the Study:

  • To investigate the role of the HCMV tegument protein pp150 in regulating the host cell cycle during productive infection.
  • To determine the physiological relevance of pp150's interaction with cyclin A in HCMV replication.
  • To elucidate the cooperative mechanism between pp150 and pUL21a in HCMV cell cycle manipulation.

Main Methods:

  • Employing a pp150 mutant virus deficient in cyclin A binding.
  • Analyzing the impact of viral gene expression on host cell cycle progression (G2/M arrest).
  • Assessing viral replication and cell viability in cells infected with wild-type and mutant HCMV strains.

Main Results:

  • Unrestricted viral gene expression in S/G2 phases led to G2/M arrest.
  • G2-arrested cells supported viral replication, while mitotic cells did not.
  • The viral protein pUL21a destabilized cyclin A, maintaining the G2-arrest.
  • Disabling both pp150 and pUL21a interactions with cyclin A resulted in mitotic entry, reduced cell viability, and impaired virus growth.

Conclusions:

  • HCMV pp150 restricts viral gene expression in S/G2 phases by binding to cyclin A.
  • HCMV employs a cell cycle synchronization strategy involving pp150 and pUL21a to target cyclin A.
  • This coordinated targeting and avoidance of cyclin A is essential for productive HCMV infection and optimal virus yield.

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.5K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
40.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K